How much funding has Aiosyn raised?

Aiosyn has raised $4.94M in total funding. Their latest funding round was Seed Round. Key investors include TNO Ventures, Oost NL, LUMO Labs, Health Innovations.

Where is Aiosyn headquartered?

Aiosyn is headquartered in Nijmegen, Gelderland, The Netherlands. The company has a team of 11-50 people.

Aiosyn operates in the AI in Healthcare sector. Aiosyn develops AI-powered pathology software for cancer and kidney disease diagnostics, designed to be seamlessly integrated into existing clinical workflows. To enhance the accuracy, efficiency, and consistency of pathological diagnoses by providing AI-powered tools that assist pathologists in their decision-making process and streamline their workflow.

When was Aiosyn founded?

Aiosyn was founded in 2021. It is based in Nijmegen, Gelderland, The Netherlands.

How much funding has Aiosyn raised?

Aiosyn has raised $4.94M in total funding. Key investors include TNO Ventures, Oost NL, LUMO Labs, Health Innovations.

Who is the CEO of Aiosyn?

Patrick de Boer is the CEO of Aiosyn. The company was founded in 2021.

Where is Aiosyn located?

Aiosyn is headquartered in Nijmegen, Gelderland, The Netherlands.

What funding stage is Aiosyn at?

Aiosyn is currently at the Commercial stage.

How many employees does Aiosyn have?

Aiosyn has approximately 11-50 employees.

Aiosyn

Category: AI in Healthcare

Aiosyn develops AI-powered pathology software for cancer and kidney disease diagnostics, designed to be seamlessly integrated into existing clinical workflows. Aiosyn was founded in 2021. The company is led by Patrick de Boer. Based in Nijmegen, Gelderland, The Netherlands. Team size: 11-50. Total funding raised: $4.94M. Latest round: Seed Round. Key investors include TNO Ventures, Oost NL, LUMO Labs, Health Innovations.

Founded: 2021
Headquarters: Nijmegen, Gelderland, The Netherlands
Team size: 11-50
Total funding: $4.94M

Value proposition

To enhance the accuracy, efficiency, and consistency of pathological diagnoses by providing AI-powered tools that assist pathologists in their decision-making process and streamline their workflow.

Products and solutions

Aiosyn Mitosis Breast: An AI algorithm for detecting and counting mitotic figures in breast cancer tissue samples., AiosynQC: An automated quality control solution for digital pathology slides., NephroPath: AI-powered analytics for kidney biopsies., AI solutions for prostate cancer diagnosis.

Unique value

Aiosyn originated as a spin-off from the prestigious Computational Pathology research group at Radboud University Medical Center in the Netherlands, a world leader in the field. This provides the company with a strong foundation based on over 20 years of cutting-edge research.

Target customer

Pathologists, pathology laboratories, and contract research organizations (CROs) involved in clinical diagnostics and pharmaceutical research.

Industries served

Healthcare (Digital Pathology, Diagnostics), Pharmaceuticals and Biotechnology (Drug Development, Biomarker Discovery)

Technology advantage

The company's primary advantage is its focus on developing robust, scientifically validated deep learning algorithms that integrate smoothly into existing digital pathology platforms. Achieving the first CE-IVDR certification for an AI-powered mitosis detection algorithm gives them a significant regulatory and competitive edge in the market.

How they differentiate

Aiosyn focuses on developing AI-powered algorithms for pathology that can be integrated into existing digital pathology workflows. Their emphasis is on creating a seamless, open platform that works with various scanners and IT infrastructure, rather than providing a closed, end-to-end system. They have a specific focus on developing algorithms for cancer and kidney disease.

Main competitors

PathAI, Proscia, Ibex Medical Analytics

Key partnerships

Radboud University Medical Center (Founding research institution), Pramana (Collaboration for real-time AI processing on digital pathology scanners), Sectra and Paige (Integration into their digital pathology marketplaces and platforms), Physiogenex (Partnership to use AI for enhancing preclinical drug development for kidney disease), TNO (Strategic partnership for technology and business development), Pathologie-DNA (Collaboration on a grant to develop AI solutions for cancer diagnostics), Telemis (Partnership to integrate Aiosyn Mitosis Breast into Telemis viewer for breast cancer grading), Techcyte (Collaboration to integrate AI-powered slide QC and mitotic counting into Fusion platform), HistoWiz (Kidney image analysis tools available on PathologyMap)

Notable customers

Techcyte, Pramana, Telemis, HistoWiz

Major milestones

Aiosyn Mitosis Breast became the first AI-powered mitosis detection solution to achieve CE mark certification under IVDR (Jan 2025)., Entered into strategic partnerships with Telemis, Techcyte, and HistoWiz to integrate AI algorithms into digital pathology platforms., Expanded AiosynQC with incomplete scan detection and white balance issue detection., Closed €2.4M funding round led by TNO Ventures (Sept 2025)., Formed strategic partnership with TNO for technology and business development.

Growth metrics

Specific growth metrics such as revenue or number of users are not publicly available.

Market positioning

Aiosyn positions itself as a specialized developer of high-quality, deep-learning algorithms for clinical diagnostics. They often partner with other digital pathology companies to integrate their solutions into broader platforms, acting as a key component in the digital pathology ecosystem rather than a direct competitor to full-suite providers.

Geographic focus

Aiosyn is based in the Netherlands and appears to have an initial focus on the European market, with partnerships and collaborations with European companies and research institutions.

Patents and IP

Specific information regarding patents or IP is not publicly disclosed in the provided search results.

About Patrick de Boer

Serial entrepreneur in AI-based digital health technologies for diagnostics and clinical trials. Co-founder and CEO of Thirona, a company specializing in AI-powered medical image analysis. He also held business development positions at Radboudumc and was a visiting researcher at the University of Iowa.

Official website: https://www.aiosyn.com/